Combined surgeries for retroperitoneal tumors.

Abstract

e23579 Background: Retroperitoneal tumors are rare heterogeneous malignant tumors. Due to their poor response to chemoradiotherapy, surgery is the main treatment option. Currently, there is little data on treatment outcomes in patients who underwent en block resection of retroperitoneal tumors and major vessels. Our purpose was to analyze surgical and oncological results in patients with retroperitoneal tumors and major blood vessel involvement. Methods: 27 patients received surgery for retroperitoneal tumors with major vessel resection in 2015-2019. Results: The mean tumor diameter was 17 cm (11-39 cm). The most frequent histological types were moderately differentiated liposarcoma (33.4%), well differentiated (18.5%), poorly differentiated sarcoma (18.5%), pleomorphic liposarcoma (22.2%), leiomyosarcoma (7.4%). Resection of the suprarenal inferior vena cava (IVC) with prosthetics was performed in 4 cases, resection of its renal segment with renal vein reimplantation - 1, resection of the infrarenal IVC with prosthetics - 8. PTFE prostheses were used as a conduit in all cases. Marginal excision of the suprarenal IVC was performed in one patient, that of the infrarenal IVC - in 5 patients; resection of the infrarenal IVC without the reconstruction - in one case. The iliac venous segment resection was required in 6 patients, in one case – with the iliac arterial segment resection and prosthetics. Macroscopic complete resection (R0-R1) was achieved in 92.6%. The postoperative morbidity was 25.9%, with no fatal outcomes. Despite the anticoagulant therapy, the frequency of thrombosis of the venous reconstruction area in the early postoperative period (1 month) was 7.4%. The median relapse-free survival was 14 months; the median overall survival was not achieved. Conclusions: Combined surgeries with simultaneous removal of retroperitoneal tumor and angioplasty demonstrate an acceptable level of morbidity and mortality. Radical removal of tumors with major blood vessel involvement allows increasing the survival in patients often considered inoperable.

Review of MXene-Derived Quantum Dots for Cancer Theranostics

“…The treatment effect of cancer are not only related to the existing medical technology, but also affected by many uncertainties, such as delayed detection, serious complications, and delayed treatment due to the pandemic and natural disasters, which would lead to lower cure rate of cancer . Currently, the clinical treatment methods for cancer contain surgery, chemotherapy, radiotherapy, thermotherapy, and high intensity focused ultrasound (HIFU) therapy, , but the efficiency and effectiveness are limited by the complexity and heterogeneity of tumoral tissues . The early diagnosis and effective treatment of cancer are of significance to improve the survival rate and relieve the discomfort of patients .…”

Nanoparticles with Active Targeting Ability and Acid Responsiveness for an Enhanced Antitumor Effect of Docetaxel

“…Malignant tumors, commonly known as cancer, represent the second leading cause of death worldwide and pose a significant public health challenge . Current cancer treatments include surgery, , radiotherapy, − chemotherapy, − and immunotherapy. , Chemotherapy, in particular, plays a pivotal role in inhibiting cancer cell growth. However, chemotherapeutic drugs suffer from several limitations, such as poor solubility, low bioavailability, and lack of tumor-targeting ability. , Moreover, they often result in severe adverse effects, such as alopecia, vomiting, myelosuppression, nephrotoxicity, and mucositis, thereby restricting their clinical use. − In recent years, there has been a growing interest in nano-anticancer drugs that aim to maximize therapeutic efficacy while minimizing toxic side effects associated with chemotherapeutic agents. , …”